Nutrition & metabolism · Colorado Springs, CO
Nutrition and metabolism studies in Colorado Springs, CO
6 recruiting studies have a site in Colorado Springs.
6 recruiting studiesSource: ClinicalTrials.gov, refreshed October 26, 2026How we list studies
Studies
- RecruitingPhase 3
A Study Evaluating Efruxifermin in Subjects With Non-Cirrhotic Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Fibrosis
Akero Therapeutics, Inc
- Location
- Colorado Springs, CO + 131 other US sites
- Eligibility basics
- Ages 18–80
- RecruitingPhase 3
LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis
Boehringer Ingelheim
- Location
- Colorado Springs, CO + 154 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis
Boehringer Ingelheim
- Location
- Colorado Springs, CO + 123 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 2
A Study to Test Whether BI 3802876 is Tolerated in People With Compensated Liver Cirrhosis Due to Metabolic Dysfunction- Associated Steatohepatitis (MASH)
Boehringer Ingelheim
- Location
- Colorado Springs, CO + 18 other US sites
- Eligibility basics
- Ages 18–75
- RecruitingPhase 3
A Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH
Akero Therapeutics, Inc
- Location
- Colorado Springs, CO + 130 other US sites
- Eligibility basics
- Ages 18–80
- RecruitingPhase 3
A Pivotal Clinical Study to Investigate Efimosfermin Alfa in Participants With Biopsy-confirmed F2- or F3-stage MASH
GlaxoSmithKline
- Location
- Colorado Springs, CO + 62 other US sites
- Eligibility basics
- Ages 18–75
Who these studies look for
Expect limits on supplements, alcohol and diet changes during the study, and sometimes a set BMI range.
Matching a page like this one never means you qualify. Each research team decides eligibility at screening.